Correlation between Demographics, Clinical and Risk Factors for HIV Infection with HIV/TB Co‑infection in Amertha Clinic Kerti Praja Foundation Denpasar
DOI:
https://doi.org/10.53638/phpma.2018.v2.i2.p01Keywords:
koinfeksi HIV/TB, terapi ARV, CD4, IDU, BaliAbstract
Background and purpose: HIV infection increases the risk of developing tuberculosis (TB), as TB infection increases the progression of HIV. In Bali, HIV/TB co-infected patients have increased from 26% in 2012 to 30% in 2013. Study on factors related with the occurrence of HIV/TB co-infection is limited in Indonesia. This study aims to determine the correlation between demographics, clinical and risk factors for HIV infection with HIV/TB co-infection in Amertha Clinic
Kerti Praja Foundation Bali.
Methods: The study design was cross-sectional using secondary data of patients with HIV/AIDS who were receiving antiretroviral therapy (ART) from 2002-2012. Independent variables were demographics: gender, age, education level, working status, and presence of ART supervisor; clinical: hemoglobin count, weight, CD4 count; and risk factor for HIV infected. The status of HIV/TB co-infection was the dependent variable. Data was analysed using univariate, bivariate (chi-square) and multivariate (cox regression).
Results: From the 531 patients, the majority were male (57.6%) and aged ≥31 years (50.8%). About 5.5% of patients experienced HIV/TB coinfection. Multivariate analysis indicated that the variables correlating with HIV/TB co-infection occurrence were CD4 count at baseline ≤200 cell/mm3 (PR=10.34; 95%CI: 1.39-76.69; p=0.022) and risk factor for HIV infected with IDU (PR=3.27; 95%CI: 1.56-6.88; p=0.002).
Conclusion: Patients with CD4 count ≤200 cell/mm3 and HIV infected by IDU have correlating with HIV/TB co-infection.
References
UNAIDS. Global report UNAIDS report on the global AIDS epidemic. 2013.
Tuberkulosis Indonesia. TB/HIV [Internet]. 2014 [cited 2014 Apr 28]. Available from: http://www.tbindonesia. or.id/tb-hiv/
Dinas Kesehatan Provinsi Bali. Laporan tahunan dinas kesehatan Provinsi Bali tahun 2013. Denpasar; 2013.
Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan Kementrian Kesehatan Republik Indonesia. Petunjuk teknis tata laksana klinis koinfeksi TB-HIV. 2012. p. 14.
Lubis R. Ko-infeksi HIV/AIDS dan TB. Departemen Epidemiologi FKM Universitas Sumatra Utara. 2000;76–81.
Kementrian Kesehatan RI. Tentang laporan situasi terkini tuberculosis di Indonesia tahun 2011. Jakarta; 2012.
Taha M, Deribew A, Tessema F, Assegid S, Colebunders R. Risk factors of active tuberculosis in people living with HIV/AIDS in Southwest Ethiopia: a case control study. Ethiop J Health Sci. 2011;21(2):131–9.
Radji M. Imunologi dan virologi. Jakarta: PT. ISFI Penerbitan; 2010.
Carvalho BM De, Monteiro AJ, Pires J. Factors related to HIV/tuberculosis coinfection in a Brazilian Reference Hospital. The Brazilian Journal of Infectious Diseases 2008;12(4):281–6.
Bellamy R, Beyers N, McAdam KP, Ruwende C, Gie R, Samaai P, et al. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jul 5;97(14):8005–9.
Moore D, Liechty C, Ekwaru P, Were W, Mwima G, Solberg P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS. 2007;21:713–9.
Fajrin KPN. Evaluasi terapi terhadap perubahan CD4 dan berat badan dan terapi OAT terhadap perubahan berat badan pada pasien koinfeksi TB/HIV di unit pelayanan terpadu HIV RSUP DR. Cipto Mangunkusumo tahun 2009. Universitas Indonesia; 2012.
Fredy FC, Liwang F, Kurniawan R, Nasir AUZ. The corelation between CD4+ t-lymphocyte count and tuberculosis form in TB-HIV coinfected patients in Indonesia. Acta Medica Indonesiana-The Indonesian Journal of Internal Medicine. 2011;44(2):122–7.
Lawn SD, Badri M, Wood R, Town C. Tuberculosis among HIV-infected patients receiving HAART : long term incidence and risk factors in a South African cohort. AIDS 2005;19:2109–16.
Permitasari DA. Faktor risiko terjadinya koinfeksi tuberkulosis pada pasien HIV/AIDS di RSUP dr. Kariadi Semarang. Program Pendidikan Sarjana Kedokteran. Fakultas Kedokteran Universitas Diponegoro. Universitas Diponegoro; 2012.
Yayasan Kerti Praja. Profil Yayasan Kerti Praja Bali [Internet]. 2014 [cited 2014 Jun 18]. Available from: http:// www.kertiprajafoundation.com/
Kassa, Desta, Leonie Ran, Wudneh Weldemeskel, Mekashaw Tebeje, Amelewerk Alemu YA. Clinical, hemato-immunological characteristics of mycobacterium tuberculosis patients with and without HIV-1 infection: responses to six month tuberculosis treatment. Biomedicine International 2012;3: 22–33.
Lyanda A. Rapid TB test. Jurnal Tuberkulosis Indonesia 2012;8:12–7.
Batungwanayo J, Taelman H, Hote R. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis. 1992;17(1):53–6.
Hirsch HH, Kaufmann G SP. Immune reconstitution in HIV-infected patients. Clin Infect Dis. 2004;38(8):1159–66.
Riadi A. Tuberkulosis dan HIV/AIDS. Jurnal Tuberkuloasi Indonesia 2012;8:22–9.
Menteri Kesehatan RI. Surat edaran nomor 129 tahun 2013 tentang pelaksanaan pengendalian HIV/AIDS dan infeksi menular seksual (IMS). Jakarta; 2013.
Framitasa D, Elita D, Gemiana D, RP EA, Noor E. Makalah diskusi kasus TB HIV. RSPI Sulianti Saroso; 2012.
Meijerink H, Wisaksana R, Iskandar S, Alisjahbana B, Heijer M den, Ven A van der, et al. Chapter 7 Injecting drug use is associated with a more rapid CD4 cell decline and a higher risk of tuberculosis among HIV-infected patients in Indonesia. PDF hosted at the Radboud Repository of the Radboud University Nijmegen. 2010. p. 103–20.
Yayasan Spiritia. Serial buku kecil hepatitis virus dan HIV. Jakarta; 2005.
Departemen Kesehatan RI. Pharmaceutical care untuk penyakit hati. Jakarta; 2007.
Greub G, B L, Battegay M. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV co infection. Lancet 2000;356:1800–5.
Wang J, Barke RA, Ma J, Charboneau R, Roy S. Opiate abuse, innate immunity, and bacterial infectious diseases. Archivum Immunologiae et Therapiae Experimentalis 2008;56(5):299–309.
Meijerink H, Wisaksana R, Iskandar S, Heijer M den, Ven A van der, Alisjahbana B, et al. Injecting drug use is associated with a more rapid CD4 cell decline among treatment naive HIV-positive patients in Indonesia. Jurnal of International AIDS Society 2004; 17(1): 18844.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Yuneti Octavianus Nyoko, I Wayan Gede Artawan Eka Putra, Anak Agung Sagung Sawitri
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
**Creative Commons Attribution 4.0 International License (CC BY 4.0)**
*Welcome to the world of open collaboration and shared creativity! The Creative Commons Attribution 4.0 International License (CC BY 4.0) empowers creators to share their work with the world while maintaining certain rights.*
**Key Points:**
1. **Freedom to Share:** CC BY 4.0 allows creators to share their work globally, granting others the freedom to use, remix, and build upon it.
2. **Attribution Requirement:** Users can use the work for any purpose, even commercially, as long as they provide appropriate credit to the original creator.
3. **Flexibility:** Applicable to various content types—text, images, music, videos—the license fosters a diverse range of creations.
**Common Use Cases:**
- **Education:** Widely used for educational materials, promoting open learning environments.
- **Research:** Applied to scholarly articles, accelerating the dissemination of knowledge.
**How to Use:**
1. **Share:** Share your work with the world, marking it with the CC BY 4.0 license.
2. **Attribution:** Users, when utilizing the work, must provide proper attribution to honor the original creator.
**Conclusion:**
CC BY 4.0 contributes to a more open and collaborative digital landscape. Join the movement of shared knowledge and creativity!
*For full license details, visit [Creative Commons](https://creativecommons.org/licenses/by/4.0/).*
